NCT03011086

Brief Summary

The etiology of OSMF is considered to be multifactorial. However, Role of autoimmunity had been suggested as one of the factors but remains unproven. The present study is undertaken to evaluate the presence of auto antibodies in OSMF patients to pave a way for new arena of treatment with the etiology of this persistent condition

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2015

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

November 7, 2016

Completed
2 months until next milestone

First Posted

Study publicly available on registry

January 5, 2017

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2017

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

December 19, 2017

Status Verified

December 1, 2017

Enrollment Period

2.8 years

First QC Date

November 7, 2016

Last Update Submit

December 18, 2017

Conditions

Keywords

Autoantibodies, Oral Submucous Fibrosis

Outcome Measures

Primary Outcomes (1)

  • Evaluation of auto antibodies in oral sub mucous fibrosis

    The subjects in the study suffering from oral submucous fibrosis will be clinically evaluated and graded based on criteria given by Khanna et al classification. All the subjects included in the study will also be subjected to serum analysis for presence of auto antibodies in their serum by Titerplane technique.

    one and half year

Study Arms (2)

oral sub mucous fibrosis

patients suffering with oral sub mucous fibrosis due to gutka/pan chewing confirmed by clinical examination

control group

patients having gutka/ pan chewing habit without oral sub mucous fibrosis in oral cavity

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

A total number of patients were 70 patients (Group A- 35 OSMF patients, Group B- 35 controls) of both the genders

You may qualify if:

  • Patients who are willing for the study.
  • A positive history of chewing arecanut, and/or smoking tobacco and alcohol.
  • Patients with clinical and histopathological features of oral submucous fibrosis.
  • Patients with OSMF not under any treatment for the same

You may not qualify if:

  • Unwilling patients who do not want to be part of the study.
  • Patients with known autoimmune disorders.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Panineeya Institute of Dental Sciences

Hyderabad, Telangana, 500060, India

Location

MeSH Terms

Conditions

Oral Submucous Fibrosis

Condition Hierarchy (Ancestors)

Mouth DiseasesStomatognathic Diseases

Study Officials

  • NALLAN CHAITANYA, MDS

    ASSOCIATE PROFESSOR

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
ASSOCIATE PROFESSOR, DEPARTMENT OF ORAL MEDICINE AND RADIOLOGY

Study Record Dates

First Submitted

November 7, 2016

First Posted

January 5, 2017

Study Start

January 1, 2015

Primary Completion

November 1, 2017

Study Completion

December 1, 2017

Last Updated

December 19, 2017

Record last verified: 2017-12

Data Sharing

IPD Sharing
Will not share

Locations